19:25 , Jul 16, 2018 |  BC Extra  |  Politics & Policy

Brexit proposal details U.K.'s intent to stay in EMA

In a white paper released Friday, the U.K. reaffirmed its desire to remain in EMA and to establish a science and innovation accord with the EU. The document detailed how the U.K. believes that drug manufacturers...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Company News

Vertex, NHS trade barbs over CF pricing

NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to resolve a stalemate over Orkambi lumacaftor/ivacaftor at their latest meeting to discuss reimbursement of the cystic fibrosis drug. While the two parties released terse statements July 5...
19:59 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Stealth, AOBiome propose Hong Kong offerings

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on July 3 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on June 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Deal puts liver-targeted mRNA therapies on horizon for BioNTech, Genevant

A pair of deals between BioNTech AG (Mainz, Germany) and Genevant Sciences will propel mRNA-based therapeutics for rare diseases into the clinic as soon as 2020 and allow BioNTech to harness the liver's robust protein...
22:59 , Jul 12, 2018 |  BC Innovations  |  Strategy

HEAL-ing pain at NIH

In a move that could change how pain is studied and treated, NIH is planning a series of projects to build a platform for translational research that is more predictive and reproducible than the current...
22:53 , Jul 12, 2018 |  BC Extra  |  Politics & Policy

ICER panel votes against elagolix for endometriosis

An ICER panel showed little confidence in the clinical effectiveness of elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) to treat endometriosis, voting Thursday that evidence is not adequate to support a net health benefit over other...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...